RCUS
Arcus Biosciences, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-10 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
19,799 |
| 2026-07-10 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
268 |
| 2026-07-09 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
48,502 |
| 2026-06-24 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
6,431 |
| 2026-06-23 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
1,697 |
| 2026-06-23 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
14,067 |
| 2026-06-22 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
9,236 |
| 2026-06-11 | Tang Carolyn C. |
General Counsel |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option is fully vested and has been completely exercised. |
Stock Option (Right to Buy)
|
34,090 |
| 2026-06-11 | Machado Patrick |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
Common Stock
|
5,700 |
| 2026-06-11 | Tang Carolyn C. |
General Counsel |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
34,090 |
| 2026-06-11 | FALBERG KATHRYN E |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
Common Stock
|
5,700 |
| 2026-06-11 | Lambert Nicole |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Stock Option (Right to Buy)
|
16,900 |
| 2026-06-11 | KANEKO YASUNORI |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
Common Stock
|
5,700 |
| 2026-06-11 | PERLMAN ANDREW J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
Common Stock
|
5,700 |
| 2026-06-11 | Ribas Antoni |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Stock Option (Right to Buy)
|
16,900 |
| 2026-06-11 | FALBERG KATHRYN E |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Stock Option (Right to Buy)
|
16,900 |
| 2026-06-11 | Lambert Nicole |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
Common Stock
|
5,700 |
| 2026-06-11 | PERLMAN ANDREW J |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Stock Option (Right to Buy)
|
16,900 |
| 2026-06-11 | Machado Patrick |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Stock Option (Right to Buy)
|
16,900 |
| 2026-06-11 | Lacey David L. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
Common Stock
|
5,700 |
| 2026-06-11 | KANEKO YASUNORI |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Stock Option (Right to Buy)
|
16,900 |
| 2026-06-11 | Lacey David L. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
Stock Option (Right to Buy)
|
16,900 |
| 2026-06-11 | Ribas Antoni |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
Common Stock
|
5,700 |
| 2026-06-01 | Azoy Alexander |
Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
2,562 |
| 2026-05-11 | Goeltz II Robert C. |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Includes the unvested portion of the reporting person's RSU grants. |
Common Stock
|
7,763 |
| 2026-01-23 | Jaen Juan C. |
President |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
31,000 |
| 2026-01-23 | Azoy Alexander |
Chief Accounting Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
21,050 |
| 2026-01-23 | Goeltz II Robert C. |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Stock Option (right to buy)
|
96,000 |
| 2026-01-23 | Markus Richard |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Stock Option (right to buy)
|
96,000 |
| 2026-01-23 | Tang Carolyn C. |
General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Stock Option (right to buy)
|
96,000 |
| 2026-01-23 | ROSEN TERRY J |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Stock Option (right to buy)
|
315,000 |
| 2026-01-23 | Tang Carolyn C. |
General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
24,000 |
| 2026-01-23 | Markus Richard |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
24,000 |
| 2026-01-23 | Azoy Alexander |
Chief Accounting Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Stock Option (right to buy)
|
14,050 |
| 2026-01-23 | Jaen Juan C. |
President |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Stock Option (right to buy)
|
126,000 |
| 2026-01-23 | Jarrett Jennifer |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
31,000 |
| 2026-01-23 | ROSEN TERRY J |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
79,000 |
| 2026-01-23 | Jarrett Jennifer |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. |
Stock Option (right to buy)
|
126,000 |
| 2026-01-23 | Goeltz II Robert C. |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. |
Common Stock
|
24,000 |
| 2026-01-08 | ROSEN TERRY J |
Director, Chief Executive Officer |
Gift↓
Filing footnotes — Common Stock (Direct)
Represents a charitable gift by the reporting person. Includes the unvested portion of the reporting person's RSU grants. |
Common Stock
|
35,000 |
| 2026-01-05 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.975 to $21.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
29,670 |
| 2026-01-05 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.04 to $22.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Common Stock
(I)
|
2,053 |
| 2026-01-05 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Indirect)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025. |
Common Stock
(I)
|
100 |
| 2025-12-31 | Goeltz II Robert C. |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
Common Stock
|
6,552 |
| 2025-12-30 | ROSEN TERRY J |
Director, Chief Executive Officer |
Gift↓
Filing footnotes — Common Stock (Direct)
2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. |
Common Stock
|
2,400 |
| 2025-12-18 | Azoy Alexander |
Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.90 to $22.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes the unvested portion of the reporting person's RSU grants. |
Common Stock
|
4,343 |
| 2025-12-17 | Jaen Juan C. |
President |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes the unvested portion of the reporting person's RSU grants. |
Common Stock
|
9,983 |
| 2025-12-17 | Azoy Alexander |
Chief Accounting Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes the unvested portion of the reporting person's RSU grants. |
Common Stock
|
2,113 |
| 2025-12-17 | ROSEN TERRY J |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes 236 shares purchased on November 30, 2025 through the Company's Employee Stock Purchase Plan. Includes the unvested portion of the reporting person's RSU grants. |
Common Stock
|
25,744 |
| 2025-12-17 | Goeltz II Robert C. |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes the unvested portion of the reporting person's RSU grants. |
Common Stock
|
5,960 |